Table 2.
Laboratory findings before and after administration of tofogliflozin for 48 weeks
| n = 17 | Week 0 | Week 48 | p value |
|---|---|---|---|
| Blood cell counts | |||
| WBC (×104/μL) | 0.68 ± 0.18 | 0.64 ± 0.18 | 0.20 |
| RBC (×104/μL) | 458 ± 37 | 488 ± 45 | 0.006 |
| Hct (%) | 40.3 ± 3.4 | 43.2 ± 3.5 | 0.002 |
| Plt (×104/μL) | 25.4 ± 6.3 | 24.5 ± 5.8 | 0.26 |
| Biochemistry | |||
| Total protein (g/dL) | 7.0 ± 0.4 | 7.1 ± 0.5 | 0.38 |
| Albumin (mg/dL) | 4.2 ± 0.4 | 4.3 ± 0.4 | 0.52 |
| Triglyceride (mg/dL) | 190 ± 101 | 184 ± 152 | 0.85 |
| HDL cholesterol (mg/dL) | 52.7 ± 12.3 | 56.8 ± 14.3 | 0.22 |
| LDL cholesterol (mg/dL) | 111 ± 18 | 114 ± 21 | 0.45 |
| AST (IU/L) | 22.7 ± 6.7 | 21.1 ± 8.8 | 0.31 |
| ALT (IU/L) | 32.5 ± 19.0 | 25.9 ± 18.5 | 0.007 |
| LDH (IU/L) | 175 ± 25 | 173 ± 36 | 0.80 |
| ALP (IU/L) | 226 ± 83 | 235 ± 84 | 0.42 |
| γ-GTP (IU/L) | 33.8 ± 15.3 | 25.6 ± 10.8 | 0.004 |
| BUN (mg/dL) | 12.2 ± 3.5 | 15.0 ± 4.2 | <0.001 |
| Creatinine (mg/dL) | 0.75 ± 0.25 | 0.80 ± 0.28 | 0.01 |
| eGFR (ml/min/1.73 m2) | 78.9 ± 20.0 | 72.3 ± 17.5 | 0.01 |
| Uric acid (mg/dL) | 5.5 ± 1.7 | 6.4 ± 5.4 | 0.48 |
| Plasma osmolality (mOsm) | 283.5 ± 4.26 | 287.1 ± 23.7 | 0.56 |
| Glucose metabolism | |||
| HbA1c (%) | 7.8 ± 1.6 | 7.1 ± 1.2 | 0.005 |
| GA (%) | 17.2 ± 3.5 | 15.4 ± 2.7 | 0.02 |
| Casual plasma glucose (mg/dL) | 161 ± 60 | 124 ± 33 | 0.009 |
| CPR index | 2.05 ± 0.9 | 2.42 ± 1.40 | 0.10 |
| Glucagon (pg/mL) | 195 ± 41 | 188 ± 49 | 0.49 |
| Total ketone bodies (μmol/L) | 91.3 ± 56.7 | 136.4 ± 157.1 | 0.14 |
Values are the mean ± SD
WBC white blood cells, RBC red blood cells, Hct hematocrit, Plt platelets, HDL high-density lipoprotein, LDL low-density lipoprotein, AST aspartate aminotransferase, ALT alanine aminotransferase, LDH lactate dehydrogenase, ALP alkaline phosphatase, γ-GTP γ-glutamyl transpeptidase, BUN blood urea nitrogen, eGFR estimated glomerular filtration rate, HbA1c hemoglobin A1c, GA glycoalbumin, CPR index C-peptide immunoreactivity index